Asset Details
Do you wish to reserve the book?
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device
Do you wish to request the book?
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device
2005
Overview
This clinical delivery system bridging study evaluated the performance of a single-use disposable, commercial prototype device (designated ND5.5) for particle-mediated epidermal delivery (PMED) of a nucleic acid vaccine against Hepatitis B virus (HBV). Healthy adults, previously immunized with licensed HBV vaccine, received a single boost vaccination of HBV nucleic acid vaccine administered by ND5.5 or XR-1, the clinical research device used in previous clinical trials. Similar increases in anti-HBV surface antigen serum antibody titers and cell-mediated immune responses were produced by ND5.5 and XR-1 when delivering comparable effective doses of the vaccine. The overall intensity of the immune response was lower in those subjects vaccinated with two, rather than 4 administrations of vaccine delivered by ND5.5. Skin reactions at sites of vaccine administration were equivalent with both devices. This is the first clinical demonstration of the safe and effective PMED of a nucleic acid vaccine with the ND5.5 device.
Publisher
Elsevier Ltd,Elsevier,Elsevier Limited
Subject
/ Adult
/ Antigens
/ Biological and medical sciences
/ DNA
/ DNA, Viral - administration & dosage
/ Ethanol
/ Female
/ Fundamental and applied biological sciences. Psychology
/ Helium
/ Hepatitis B - prevention & control
/ Hepatitis B Antibodies - immunology
/ Hepatitis B Surface Antigens - immunology
/ Hepatitis B Vaccines - administration & dosage
/ Hepatitis B Vaccines - adverse effects
/ Hepatitis B Vaccines - immunology
/ Humans
/ Immunity
/ Injections, Jet - instrumentation
/ Male
/ Particle-mediated epidermal delivery
/ Skin
/ Vaccines
/ Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
/ Vaccines, DNA - administration & dosage
/ Vaccines, DNA - adverse effects
/ Virology
